Skip navigation

Office of Research & Sponsored Programs

mary reed scene

Research Integrity & Education

rDNA and Biosafety (IBC)

COVID-19 Update

The University of Denver's Institutional Biosafety Committee (IBC) is continuing to provide ongoing support of protocols involving the use of recombinant DNA and other biohazardous and chemical agents. Principal Investigators with currently active research projects will still be required to complete annual Post Approval Monitoring (PAM) Meetings with the IBC Administrator and submit 5-year renewal applications for expiring protocols, if necessary. Please contact Tyler Ridgeway (217-414-9688, or tyler.ridgeway@du.edu) with any questions regarding the status of your protocol.

Institutional Biosafety Committee (IBC)

Federal Guidelines, established by the National Institute of Health, require that institutions conducting or sponsoring research using recombinant or synthetic nucleic acid molecules, covered by the NIH Guidelines, be responsible for ensuring that the research is conducted in full conformity with the provisions of the NIH Guidelines.

bio

The University of Denver Institutional Biosafety Committee (IBC) reviews, approves, and oversees research and teaching activities that involves the use of recombinant or synthetic DNA/RNA and other biohazardous agents. The IBC's primary objective is to safeguard protection of personnel, the general public, and the environment. To meet this goal, the IBC works with the DU Environmental Health & Safety (EHS) Department to establish requirements for safe laboratory and biological safety practices and reviews and approves policies, procedures, and training programs pursuant to the safe use of biological agents, other biological materials, and toxins.

Committee Meetings

The IBC meetings are held on a quarterly basis; usually during the months of March, June, September and December from 12:00 noon to 1:00p.m.